Affordable Access

Publisher Website

Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy

Epilepsy Research
Publication Date
DOI: 10.1016/j.eplepsyres.2011.02.003
  • Cytokine
  • Idiopathic Epilepsy
  • Primary Generalized Epilepsy
  • Temporal Lobe Epilepsy
  • Biology


Summary Purpose Indoleamine 2,3-dioxygenase (IDO) is a cytokine-inducible enzyme that participates in tryptophan (trp) and serotonin metabolism with an ability to modulate neuroinflammation. Several recent studies have shown associations between cytokines and epilepsy. In this study we investigated whether activation of IDO is associated with epilepsy. Methods Kynurenine (kyn)/trp serum ratio, as an indicator of IDO activity was analyzed in 271 carefully classified epilepsy patients, and 309 healthy adults. Results IDO activity was increased in patients with unclassified idiopathic generalized epilepsy (IGE) ( n = 11; p = 0.05), in juvenile myoclonic epilepsy (JME) ( n = 25; p = 0.04) and in patients those with temporal lobe epilepsy but no hippocampal sclerosis (TLE-HS) ( n = 103; p = 0.05) compared to the control subjects. In patients with idiopathic (but not cryptogenic or symptomatic) etiology of epilepsy, IDO activity was increased compared to the control subjects ( p < 0.05). Patients with extra-TLE or TLE + HS had IDO activity comparable to the control subjects. Patients who were one-month seizure-free prior to sampling had increased IDO activity compared to the control subjects ( p = 0.03). Conclusions Increased IDO activity appeared to be associated with idiopathic generalized epilepsies such as unclassified IGE and JME, two of the most common types of primary generalized epilepsy. We also found a trend of increased IDO activity in patients with TLE-HS. Our results suggest that increased IDO activity may represent an adaptive metabolic phenomenon in epilepsy, which may also have a neuroprotective or anticonvulsive role by downregulating neuroinflammation in the brain.

There are no comments yet on this publication. Be the first to share your thoughts.